Risk Stratifikasyonu ve Prognoz
Özet
Pulmoner arteriyel hipertansiyon (PAH), ilerleyici pulmoner vasküler yeniden şekillenme sonucunda pulmoner vasküler direncin arttığı, sağ ventrikül (RV) yetmezliği ve erken mortalite ile seyreden ciddi bir hastalıktır. Güncel PAH yönetiminde temel hedef, hastaların risk düzeyinin doğru şekilde belirlenmesi ve düşük risk profiline ulaştırılarak bu durumun sürdürülmesidir. Bu nedenle risk stratifikasyonu, tanı ve tedavi sürecinin ayrılmaz bir bileşeni haline gelmiştir. PAH’da risk değerlendirmesi; klinik bulgular, fonksiyonel sınıf, egzersiz kapasitesi, biyobelirteçler, görüntüleme yöntemleri ve invaziv hemodinamik parametrelerin birlikte değerlendirilmesine dayanmaktadır. Altı dakika yürüme testi ve kardiyopulmoner egzersiz testi fonksiyonel kapasitenin değerlendirilmesinde önemli araçlar olup, B-tipi natriüretik peptid ve N-terminal pro-B-tipi natriüretik peptid düzeyleri prognostik değeri en güçlü biyobelirteçler arasında yer almaktadır. Ekokardiyografi ve kardiyak manyetik rezonans görüntüleme, sağ ventrikül yapı ve fonksiyonlarının değerlendirilmesinde önemli bilgiler sağlamakta; özellikle sağ ventrikül–pulmoner arter etkileşimi, sağ kalpte tersine yeniden şekillenme ve sağ ventrikül fonksiyonu güncel prognostik yaklaşımlarda ön plana çıkmaktadır. Güncel risk değerlendirme modelleri, mortalite ve klinik kötüleşme riskinin öngörülmesinde ve tedavi kararlarının yönlendirilmesinde yaygın olarak kullanılmaktadır. Dinamik ve düzenli risk değerlendirmesi, tedavi yanıtının izlenmesi ve uzun dönem klinik sonuçların iyileştirilmesi açısından kritik öneme sahiptir. Günümüzde tedavinin temel amacı, hastaların düşük risk düzeyine ulaştırılması ve bu durumun sürdürülebilmesidir.
Pulmonary arterial hypertension (PAH) is a serious disease characterized by progressively increasing pulmonary vascular resistance as a result of progressive pulmonary vascular remodeling, leading to right ventricular (RV) failure and early mortality. The central goal of contemporary PAH management is to accurately determine each patient's risk level and to achieve and maintain a low-risk profile. For this reason, risk stratification has become an integral component of the diagnostic and therapeutic process. Risk assessment in PAH is based on the combined evaluation of clinical findings, functional class, exercise capacity, biomarkers, imaging modalities, and invasive hemodynamic parameters. The six-minute walk test and cardiopulmonary exercise testing are important tools for assessing functional capacity, while B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide levels are among the biomarkers with the strongest prognostic value. Echocardiography and cardiac magnetic resonance imaging provide important information for evaluating right ventricular structure and function; in particular, right ventricular–pulmonary artery coupling, reverse remodeling of the right heart, and right ventricular function have come to the forefront in current prognostic approaches. Current risk assessment models are widely used to predict mortality and the risk of clinical worsening, and to guide treatment decisions. Dynamic and regular risk assessment is critically important for monitoring treatment response and improving long-term clinical outcomes. Today, the primary goal of treatment is to bring patients to a low-risk status and to sustain this condition.
Referanslar
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi: 10.1183/13993003.01913-2018.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi: 10.1183/13993003.00879-2022.
Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H, et al. Risk stratification and treatment goals in pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401323. doi: 10.1183/13993003.01323-2024.
Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1):2102311. doi: 10.1183/13993003.02311-2021.
Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi: 10.1183/13993003.00889-2017.
Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354-362. doi: 10.1378/chest.11-0676.
Hjalmarsson C, Thakur T, Weiss T, Björklund E, Papageorgiou JM, Rådegran G, et al. Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis. J Heart Lung Transplant. 2025;44(11):1787-1797. doi: 10.1016/j.healun.2024.10.029.
Haddad F, Contrepois K, Amsallem M, Denault AY, Bernardo RJ, Jha A, et al. The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension. Chest. 2022;161(5):1347-1359. doi: 10.1016/j.chest.2021.10.045.
Lokhorst C, van der Werf S, Berger RMF, Douwes JM. Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review. J Am Heart Assoc. 2024;13(13):e034151. doi: 10.1161/JAHA.123.034151.
Xanthouli P, Koegler M, Marra AM, Benjamin N, Fischer L, Eichstaedt CA, et al. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. Respir Res. 2020;21(1):127. doi: 10.1186/s12931-020-01393-1.
Forbes LM, Bull TM, Lahm T, Make BJ, Cornwell WK 3rd. Exercise Testing in the Risk Assessment of Pulmonary Hypertension. Chest. 2023;164(3):736-746. doi: 10.1016/j.chest.2023.04.013.
Baccelli A, Rinaldo RF, Haji G, Davies RJ, Lo Giudice F, Gin-Sing W, et al. Prognostic value of cardiopulmonary exercise testing in pulmonary arterial hypertension. Eur Respir J. 2025;66(2):2402026. doi: 10.1183/13993003.02026-2024.
Kylhammar D, Kjellström B, Hjalmarsson C, Jansson K, Nisell M, Söderberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-4181. doi: 10.1093/eurheartj/ehx257.
McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006;15(1):103-15. doi: 10.1007/s11136-005-3513-4.
Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014;43(4):1106-13. doi: 10.1183/09031936.00127113.
McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schüler R, et al. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res. 2016;17(1):72. doi: 10.1186/s12931-016-0388-6.
Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, et al. Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. Am J Respir Crit Care Med. 2021;203(6):761-764. doi: 10.1164/rccm.202010-3967LE. Erratum in: Am J Respir Crit Care Med. 2022;206(3):362-363. doi: 10.1164/rccm.v206erratum3.
Zhai Y, Li A, Tao X, Gao Q, Xie W, Zhang Y, et al. Predicting high-risk pre-capillary pulmonary hypertension: an echocardiographic multiparameter scoring index. BMC Cardiovasc Disord. 2024;24(1):384. doi: 10.1186/s12872-024-04053-0.
Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, et al. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2017:S1053-2498(17)32041-7. doi: 10.1016/j.healun.2017.09.026.
Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034-41. doi: 10.1164/rccm.200604-547OC.
Tello K, Richter MJ, Axmann J, Buhmann M, Seeger W, Naeije R, et al. More on Single-Beat Estimation of Right Ventriculoarterial Coupling in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018;198(6):816-818. doi: 10.1164/rccm.201802-0283LE.
Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, et al. Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circ Cardiovasc Imaging. 2019;12(9):e009047. doi: 10.1161/CIRCIMAGING.119.009047.
Swift AJ, Rajaram S, Capener D, Elliot C, Condliffe R, Wild JM, et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2014;7(1):100-106.
Alabed S, Shahin Y, Garg P, Alandejani F, Johns CS, Lewis RA, et al. Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. 2021;14(5):931-942. doi: 10.1016/j.jcmg.2020.08.013. Erratum in: JACC Cardiovasc Imaging. 2021;14(4):884. doi: 10.1016/j.jcmg.2021.02.001.
Zhong L, Leng S, Alabed S, Chai P, Teo L, Ruan W, et al. Pulmonary Artery Strain Predicts Prognosis in Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2023;16(8):1022-1034. doi: 10.1016/j.jcmg.2023.02.007.
D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-9. doi: 10.7326/0003-4819-115-5-343.
Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019;156(2):323-337. doi: 10.1016/j.chest.2019.02.004.
